Biosensors International develops, manufactures and markets pioneering interventional cardiology devices.
The BioMatrix™ DES family features Biolimus A9™ (BA9™), a highly lipophilic anti-restenotic drug designed for cardiovascular stent technologies patented by Biosensors, combined in a unique abluminal biodegradable polymer coating. BioMatrix Alpha™, the latest addition to the family, is a CoCr stent featuring an innovative hybrid design, thin struts and an advanced delivery system.
BioFreedom™ demonstrated superior safety and efficacy vs BMS in High Bleeding Risk patients in the landmark LEADERS FREE trial and features a selectively micro-structured abluminal surface allowing polymer & carrier free delivery of BA9™.
Recently Biosensors’ parent company made a significant investment into the rapidly growing field of structural heart disease intervention through the acquisition of the company New Valve Technology (NVT), the developers of the flagship product Allegra™ transfemoral TAVI system.
Together, Biosensors and NVT will leverage our their respective innovative expertise in Cardiovascular and Structural Heart technologies.
Our aim is to improve patients’ lives through pioneering medical technology that pushes the boundaries of innovation.
Through our high quality medical devices we impact the lives we touch and we are committed to continued investment in the development of pioneering medical technology, robust clinical data and engineering new medical devices that will further benefit your patients.
-
Industry
-
Medical Device
-
Company size
-
501-1,000 employees
-
Headquarters
-
Singapore
-
Type
-
Public Company
-
Founded
-
1990
-
Specialties
-
Cardiology medical device, Structural Heart, TAVI, Stents, Pioneering Technology, and Balloons
